A New Jersey-based pharmaceutical company has agreed to pay $25 million for allegedly engaging in a price-fixing scheme for a generic cholesterol drug.
“Illegal collaboration on the price or supply of drugs increases costs both to federal health care programs and beneficiaries,” said the Department of Justice’s (DOJ) Principal Deputy Assistant Attorney General Brian Boynton. “The department will use every tool at its disposal to prevent such conduct and to protect these taxpayer-funded programs from abuse.”
